Motif (MTFB) Receives $21.33 Consensus Target Price from Brokerages

Motif (NASDAQ:MTFB) has received an average rating of “Hold” from the six analysts that are currently covering the firm, Marketbeat reports. Two equities research analysts have rated the stock with a sell rating, one has assigned a hold rating and three have assigned a buy rating to the company. The average 1-year price objective among analysts that have issued ratings on the stock in the last year is $21.33.

Several brokerages recently issued reports on MTFB. Gabelli restated a “hold” rating on shares of Motif in a research report on Thursday, March 29th. Seaport Global Securities restated a “buy” rating on shares of Motif in a research report on Friday, December 22nd. ValuEngine upgraded shares of Motif from a “strong sell” rating to a “sell” rating in a research report on Friday, February 2nd. Finally, WBB Securities began coverage on shares of Motif in a research report on Friday, December 29th. They set a “sell” rating and a $7.00 target price for the company.

Shares of MTFB traded down $0.04 during mid-day trading on Tuesday, hitting $10.25. 4,430 shares of the company traded hands, compared to its average volume of 1,548. The stock has a market capitalization of $2,010.96, a price-to-earnings ratio of -29.28 and a beta of 0.19. Motif has a 1 year low of $6.75 and a 1 year high of $13.75.

ILLEGAL ACTIVITY NOTICE: This article was first reported by Ticker Report and is the sole property of of Ticker Report. If you are reading this article on another domain, it was illegally stolen and reposted in violation of U.S. & international trademark and copyright legislation. The original version of this article can be accessed at https://www.tickerreport.com/banking-finance/3341484/motif-mtfb-receives-21-33-consensus-target-price-from-brokerages.html.

Motif Company Profile

Motif Bio plc, a clinical stage biopharmaceutical company, develops and commercializes pharmaceutical formulations in the United States. The company develops novel antibiotics for the treatment of serious and life-threatening infections caused by multi-drug resistant bacteria. Its lead product candidate is Iclaprim, a novel antibiotic that is in Phase III clinical trials to treat bacterial infections, such as acute bacterial skin and skin structure infections, and hospital acquired bacterial pneumonia caused by methicillin-resistant staphylococcus aureus.

Analyst Recommendations for Motif (NASDAQ:MTFB)

Receive News & Ratings for Motif Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Motif and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

BidaskClub Downgrades Lands’ End  to Hold
BidaskClub Downgrades Lands’ End to Hold
NXP Semiconductors  Rating Lowered to Strong Sell at BidaskClub
NXP Semiconductors Rating Lowered to Strong Sell at BidaskClub
Pool  Stock Rating Lowered by BidaskClub
Pool Stock Rating Lowered by BidaskClub
Sunrun  Stock Rating Upgraded by BidaskClub
Sunrun Stock Rating Upgraded by BidaskClub
Upland Software  Rating Lowered to Buy at BidaskClub
Upland Software Rating Lowered to Buy at BidaskClub
FIG Partners Brokers Increase Earnings Estimates for TWO Rivers Bancorp
FIG Partners Brokers Increase Earnings Estimates for TWO Rivers Bancorp


© 2006-2018 Ticker Report. Google+.